

Variable	Unit	Value	Variable	Unit	Value
Age	Years	25.5	Height	cm	175.5
Weight	kg	75.5	Weight	kg	75.5
Body mass index	kg/m ²	24.5	Body mass index	kg/m ²	24.5
Heart rate	beats/min	75.5	Heart rate	beats/min	75.5
Stroke volume	L/min	100.5	Stroke volume	L/min	100.5
Cardiac output	L/min	7.5	Cardiac output	L/min	7.5
Mean arterial pressure	mmHg	93.5	Mean arterial pressure	mmHg	93.5
Systolic blood pressure	mmHg	120.5	Systolic blood pressure	mmHg	120.5
Diastolic blood pressure	mmHg	80.5	Diastolic blood pressure	mmHg	80.5
Pulse pressure	mmHg	40.5	Pulse pressure	mmHg	40.5
Heart rate variability	ms	50.5	Heart rate variability	ms	50.5
Respiratory rate	breaths/min	12.5	Respiratory rate	breaths/min	12.5
Tidal volume	L	1.5	Tidal volume	L	1.5
Minute ventilation	L/min	18.5	Minute ventilation	L/min	18.5
Arterial oxygen saturation	%	98.5	Arterial oxygen saturation	%	98.5
Partial pressure of oxygen	mmHg	100.5	Partial pressure of oxygen	mmHg	100.5
Partial pressure of carbon dioxide	mmHg	40.5	Partial pressure of carbon dioxide	mmHg	40.5
pH		7.38	pH		7.38
Bicarbonate	mmol/L	24.5	Bicarbonate	mmol/L	24.5
Lactate	mmol/L	1.5	Lactate	mmol/L	1.5
Glucose	mmol/L	5.5	Glucose	mmol/L	5.5
Urea nitrogen	mmol/L	5.5	Urea nitrogen	mmol/L	5.5
Creatinine	mmol/L	0.5	Creatinine	mmol/L	0.5
Sodium	mmol/L	140.5	Sodium	mmol/L	140.5
Potassium	mmol/L	4.0	Potassium	mmol/L	4.0
Calcium	mmol/L	1.0	Calcium	mmol/L	1.0
Magnesium	mmol/L	0.5	Magnesium	mmol/L	0.5
Phosphorus	mmol/L	0.5	Phosphorus	mmol/L	0.5
Chloride	mmol/L	100.5	Chloride	mmol/L	100.5
Bilirubin	mmol/L	0.5	Bilirubin	mmol/L	0.5
Albumin	g/L	40.5	Albumin	g/L	40.5
Protein	g/L	70.5	Protein	g/L	70.5
Triglycerides	mmol/L	1.5	Triglycerides	mmol/L	1.5
Cholesterol	mmol/L	5.5	Cholesterol	mmol/L	5.5
HDL cholesterol	mmol/L	1.5	HDL cholesterol	mmol/L	1.5
LDL cholesterol	mmol/L	3.5	LDL cholesterol	mmol/L	3.5
Very low density lipoprotein	mmol/L	0.5	Very low density lipoprotein	mmol/L	0.5
Urea nitrogen	mmol/L	5.5	Urea nitrogen	mmol/L	5.5
Creatinine	mmol/L	0.5	Creatinine	mmol/L	0.5
Sodium	mmol/L	140.5	Sodium	mmol/L	140.5
Potassium	mmol/L	4.0	Potassium	mmol/L	4.0
Calcium	mmol/L	1.0	Calcium	mmol/L	1.0
Magnesium	mmol/L	0.5	Magnesium	mmol/L	0.5
Phosphorus	mmol/L	0.5	Phosphorus	mmol/L	0.5
Chloride	mmol/L	100.5	Chloride	mmol/L	100.5
Bilirubin	mmol/L	0.5	Bilirubin	mmol/L	0.5
Albumin	g/L	40.5	Albumin	g/L	40.5
Protein	g/L	70.5	Protein	g/L	70.5
Triglycerides	mmol/L	1.5	Triglycerides	mmol/L	1.5
Cholesterol	mmol/L	5.5	Cholesterol	mmol/L	5.5
HDL cholesterol	mmol/L	1.5	HDL cholesterol	mmol/L	1.5
LDL cholesterol	mmol/L	3.5	LDL cholesterol	mmol/L	3.5
Very low density lipoprotein	mmol/L	0.5	Very low density lipoprotein	mmol/L	0.5

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24

administering to said patient anti-cancer antibodies or fragments thereof produced in accordance with a method for the production of individually customized anti-cancer antibodies which are useful in treating a cancerous disease, said antibodies including a subset of antibodies or fragments thereof characterized as being cytotoxic against cells of a cancerous tissue, said subset being essentially benign to non-cancerous cells;

Claim 2. The method for treating a patient suffering from a cancerous disease in accordance with claim 1, wherein said one or more antibodies or fragments thereof selected from said subset are humanized.

1 Claim 3. The method for treating a patient suffering
2 from a cancerous disease in accordance with claim 1
3 comprising:

4 conjugating said subset of antibodies or fragments
5 thereof with a member selected from the group consisting of
6 toxins, enzymes, radioactive compounds, and hematogenous
7 cells; and

8 administering conjugated antibodies or fragments thereof
9 to said patient;

10 wherein said conjugated antibodies are placed in
11 admixture with a pharmaceutically acceptable adjuvant and are
12 administered in an amount effective to mediate treatment of
13 said cancerous disease.

14
15 Claim 4. The method of claim 3, wherein said one or
16 more antibodies or fragments thereof selected from said
17 subset are humanized.

18
19 Claim 5. The method for treating a patient suffering
20 from a cancerous disease in accordance with claim 1 wherein:
21 the cytotoxicity of said antibodies or fragments thereof
22 is mediated through antibody dependent cellular toxicity.

23
24 Claim 6. The method for treating a patient suffering
25 from a cancerous disease in accordance with claim 1 wherein:

1 the cytotoxicity of said antibodies or fragments thereof
2 is mediated through complement dependent cellular toxicity.

3
4 Claim 7. The method for treating a patient suffering
5 from a cancerous disease in accordance with claim 1 wherein:
6 the cytotoxicity of said antibodies or fragments thereof
7 is mediated through catalyzing of the hydrolysis of cellular
8 chemical bonds.

9
10 Claim 8. The method for treating a patient suffering
11 from a cancerous disease in accordance with claim 1 wherein:
12 the cytotoxicity of said antibodies or fragments thereof
13 is mediated through producing an immune response against
14 putative cancer antigens residing on tumor cells.

15
16 Claim 9. The method for treating a patient suffering
17 from a cancerous disease in accordance with claim 1 wherein:
18 the cytotoxicity of said antibodies or fragments thereof
19 is mediated through targeting of cell membrane proteins to
20 interfere with their function.

21
22 Claim 10. The method for treating a patient suffering
23 from a cancerous disease in accordance with claim 1 wherein:
24 the cytotoxicity of said antibodies or fragments thereof
25 is mediated through production of a conformational change in

1 a cellular protein effective to produce a signal to initiate
2 cell-killing.

3
4 Claim 11. The method for treating a patient suffering
5 from a cancerous disease in accordance with claim 1 wherein:
6 said method of production utilizes a tissue sample
7 containing cancerous and non-cancerous cells obtained from a
8 particular individual.

9
10 Claim 12. The method for treating a patient suffering
11 from a cancerous disease in accordance with claim 1 wherein:
12 the antibodies or fragments thereof are selected from
13 the group consisting of a 3BD-3, a 3BD-6, a 3BD-8, a 3BD-9, a
14 3BD-15, a 3BD-25, a 3BD-26 and a 3BD-27 monoclonal antibody
15 or combinations thereof.

16
17 Claim 13. The method for treating a patient suffering
18 from a cancerous disease in accordance with claim 1 wherein:
19 the antibodies or fragment thereof are produced by one
20 or more hybridoma cell lines having an ATCC Accession Number
21 selected from the group consisting of ().

22
23 Claim 14. The method for treating a patient suffering
24 from a cancerous disease in accordance with claim 1 wherein:
25 the antibodies or fragments thereof are selected from
26 the group consisting of a 1LN-1, a 1LN-12, a 1LN-14, a 2LN-

21, a 2LN-28, a 2LN-29, a 2LN-31, a 2LN-33, a 2LN-34 and a
2LN-35 monoclonal antibody or combinations thereof.

Claim 15. The method for treating a patient suffering
from a cancerous disease in accordance with claim 1 wherein:
the antibodies or fragments thereof are produced by one
or more hybridoma cell lines having an ATCC Accession Number
selected from the group consisting of ().